Klarizon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Klarizon

Property Description
Active ingredient Clarithromycin
Form Film-coated tablets
Pharmacological class Macrolide antibiotic
Common use Fights bacterial infections
Origin Semi-synthetic derivative

What Type of Medicine is Klarizon (Clarithromycin)?

Klarizon is a prescription-only medicine that belongs to the macrolide antibiotic class of drugs, and its single active ingredient is Clarithromycin. It is classified as an antibiotic because its purpose is to combat infections caused by susceptible bacteria in the body. Clarithromycin is characterized as a semi-synthetic derivative of the older, naturally occurring antibiotic Erythromycin A. This chemical modification was designed to improve its stability and absorption compared to its parent structure, differentiating it as a second-generation macrolide. Clarithromycin is an antimicrobial used to treat various types of infections.


How is Klarizon Designed to Target Infections?

The general purpose of Klarizon is to control and stop the growth of bacterial infections. Clarithromycin achieves this by functioning as a protein synthesis inhibitor, a specific mechanism that distinguishes it from other classes of antimicrobials. It works by targeting the bacteria's essential cellular machinery, specifically the 50S ribosomal subunit, which prevents them from manufacturing the proteins required for their growth and replication. This action effectively stops the bacteria from multiplying, leading to a bacteriostatic effect that allows the body's natural immune system to successfully clear the remaining microbial population.


What is the Form and Structure of Klarizon?

Klarizon is supplied as a single-compound product in the form of film-coated tablets designed for oral administration. The tablets contain the Clarithromycin active ingredient combined with an inert pharmaceutical excipient base. The inclusion of the film coating is a deliberate pharmaceutical design feature that protects the active compound from premature degradation by stomach acid, ensuring a more reliable and measured absorption into the body. This structure provides a stable and effective method for delivering a measured quantity of the compound into the bloodstream.

Regulatory References

  1. MedlinePlus Clarithromycin Profile

What side effects are possible with Klarizon?

Possible Side Effects and Safety Information

The macrolide antibiotic clarithromycin (Klarizon) is associated with an official profile of adverse reactions, which are classified by frequency and body system in regulatory documentation, such as the European Summary of Product Characteristics and U.S. FDA labeling.


Documented Adverse Reactions and Frequency

In clinical trials, the most frequent adverse reactions are often localized to the gastrointestinal system and include diarrhea, abdominal pain, nausea, vomiting, and a change in the sense of taste (dysgeusia). These effects, along with headache and insomnia, are typically classified as Common (ge 1/100 to < 1/10 of patients) in official safety documents. Less frequent effects, such as vertigo, palpitations, and jaundice, are generally classified as Uncommon (ge 1/1000 to < 1/100).


Serious Adverse Reactions and Systemic Concerns

Official regulatory documents list several serious adverse reactions, which are often classified as Not Known (frequency cannot be estimated from available data). The most critical concerns involve the Cardiac System, including QT prolongation and the risk of developing life-threatening arrhythmias such as Torsade de pointes. Cases of severe Hepatic Dysfunction and Hepatic Failure (sometimes fatal) have also been documented. Additionally, the drug is associated with severe cutaneous reactions (SCAR), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).


Safety Considerations for Specific Contexts

Specific safety notes exist for certain patient groups. For instance, in individuals with coronary artery disease (CAD), observational studies have identified a risk of all-cause mortality that becomes apparent one year or more after the end of treatment. The drug's use is officially constrained in individuals with a history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use. Furthermore, exacerbation of Myasthenia Gravis symptoms has been reported.

Overdose and Emergency Response

Overdose and When to Seek Help

The most frequently reported manifestations following the ingestion of amounts exceeding the prescribed dose are severe gastrointestinal symptoms. These documented overdose presentations include excessive abdominal pain, nausea, vomiting, and diarrhea.

Overdose has the potential to affect multiple physiological systems, and regulatory documents highlight the risk of cardiac arrhythmia, including rare cases of Torsade de Pointes and QT interval prolongation. Hepatotoxicity is also a documented risk, which can manifest as hepatic failure; fatalities have been reported in some instances.

Mandatory Emergency Actions

Immediate medical help is required for any suspected overdose. In the event that a person has collapsed, experienced a seizure, is having trouble breathing, or cannot be awakened, urgent contact with emergency services is mandated. Individuals should also contact the poison control helpline for guidance.

Overdose Management

Treatment for overdose is officially defined as symptomatic and supportive. Regulatory information states that no specific antidote is known. Due to the documented risk of severe ventricular arrhythmias, close monitoring of cardiac function is advised. Patients with severe renal impairment are noted to be at increased risk of accumulation and toxicity.

Therapeutic Uses of Klarizon

What Klarizon Treats: Main Uses and Benefits

Klarizon is applied across domains where additional symptomatic support is needed to address bacterial infections. It is commonly used to help with conditions such as community-acquired pneumonia, acute sinusitis, pharyngitis, acute otitis media, and certain skin and soft tissue infections like cellulitis.

The medication helps address symptom clusters related to systemic imbalance and localized inflammatory states, which often create noticeable physiological strain. It is often used during phases when symptoms become more noticeable, including acute exacerbations of chronic bronchitis or episodes of severe throat infection.

“Klarizon is considered relevant in contexts involving heightened systemic burden, supporting patients during difficult episodes by easing distress.”

In addition to acute uses, Klarizon is a component of multi-drug regimens used to manage the Helicobacter pylori bacteria in peptic ulcer disease and for treating or preventing systemic Mycobacterium avium Complex (MAC) infection, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Support for Inflammation and Discomfort

Regulatory References

  1. U.S. National Library of Medicine DailyMed Profile

Eligibility and Restrictions for Use

Who can and cannot use Klarizon? — Official Regulatory Information

Klarizon (Clarithromycin) is a macrolide antibiotic with strict eligibility rules defined by regulatory authorities.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated in patients with a known hypersensitivity to clarithromycin, other macrolides, or any component of the formulation. It must not be used in those with a history of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use. Klarizon is also contraindicated in patients with congenital or documented acquired QT prolongation, a history of ventricular arrhythmias (including Torsades de Pointes), or with existing hypokalemia (low potassium) or hypomagnesemia (low magnesium).

Restrictions and Special Considerations

Population/Condition Eligibility Status
Pediatric Patients Safety and efficacy are not established for infants under 6 months of age.
Severe Renal Impairment (CrCL < 30 mL/min) Use is restricted; a dose reduction of 50% is required.
Severe Hepatic Failure + Renal Impairment Contraindicated.
Pregnancy/Lactation Safety is not established. Use is only recommended when no alternative therapy is appropriate.

Co-administered Drugs

Klarizon is strictly contraindicated for use with a number of medications, including: cisapride, pimozide, ergot alkaloids (e.g., ergotamine), oral midazolam, lomitapide, and HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (specifically lovastatin and simvastatin). Concomitant use with colchicine is also contraindicated in patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Klarizon (clarithromycin) is classified in regulatory documents as a strong inhibitor of the CYP3A4 enzyme, which can significantly increase the plasma concentrations of many co-administered medicines. This core pharmacokinetic effect governs much of its official interaction profile.

Formal Contraindicated Combinations

Certain combinations are formally prohibited by regulatory authorities due to the high risk of serious adverse reactions, often related to increased plasma levels of the co-administered drug.

Interacting Substance/Class Key Restriction Documented
Lovastatin, Simvastatin Contraindicated; increased risk of rhabdomyolysis and myopathy.
Cisapride, Pimozide Contraindicated; risk of QT prolongation and serious cardiac arrhythmias.
Ergotamine, Dihydroergotamine Contraindicated; risk of acute ergot toxicity (vasospasm).
Lomitapide, Lurasidone, Ticagrelor Contraindicated; increased systemic exposure leading to serious adverse reactions.
Colchicine Contraindicated in patients with renal or hepatic impairment.

Other Documented Interaction Constraints

  • Oral Anticoagulants (e.g., Warfarin): Official reports state co-administration may potentiate anticoagulant effects and increase the risk of hemorrhage, necessitating careful monitoring.
  • Food Intake (Extended-Release Tablets): Regulatory labeling indicates that administration of the extended-release tablet without food results in an approximately 30% lower AUC (systemic exposure) of clarithromycin.
  • Zidovudine: Doses of Klarizon and Zidovudine should be separated by at least two hours in adult HIV-infected patients to avoid decreased concentrations of Zidovudine.

Mechanism of Action

Klarizon (Clarithromycin) is classified mechanistically as a protein synthesis inhibitor whose action is highly selective for bacterial targets. Its effect is initiated through two core domains of action, both of which focus on the microbial reproductive and metabolic pathways.


Targeted Blockade of Bacterial Protein Factories

This domain covers the molecular interaction where the drug specifically binds to the bacterial 50S ribosomal subunit within the cell. The resulting mechanism is the physical inhibition of the ribosomal process, which leads to the cessation of protein manufacture. This prevents the bacteria from constructing essential proteins, enzymes, and structural components necessary for their function and survival.


Arrest of Cellular Proliferation

This mechanism results in a bacteriostatic effect, meaning the drug forces the microbial population into a state of growth arrest by preventing further cell replication. This arrest in proliferation limits the growth of the microbial population, a physiological state that requires the function of the host's immune system for the subsequent clearance of the non-replicating bacteria.


Limitations: Evasion via Bacterial Resistance Pathways

The function of the mechanism is constrained by bacterial counter-defenses, primarily through two forms of acquired resistance: Target Modification (e.g., methylation of the 23S rRNA binding site) and Active Efflux (pumping the drug out of the cell). These pathways mechanically prevent the drug from reaching or effectively binding to its target, precluding the inhibition required for ribosomal function.

Dosage and Administration Information

Klarizon (Clarithromycin) is administered primarily via the oral route using film-coated tablets. The active ingredient is also available as a powder for Intravenous (IV) infusion, typically reserved for hospital settings when oral administration is not suitable. The standard immediate-release tablet regimen for adults utilizes doses of 250 mg or 500 mg, which are taken twice daily, approximately every 12 hours. This standardized schedule establishes the routine administration frequency of the medicine.

Administration of the immediate-release tablet may occur with or without food, providing flexibility for patient intake. However, it is a procedural requirement that all tablets be swallowed whole and not chewed, broken, or crushed to ensure proper delivery. For patients using the extended-release formulation, consumption with food is required.

Duration and Adjustments

The overall duration of the course is defined to be between 6 and 14 days, a requirement that specifies the total length of the therapy, even if initial symptoms improve. The medicine is also used in multi-drug regimens over 10 or 14 days for specific conditions such as H. pylori eradication. For patients with severely reduced kidney function, defined as a creatinine clearance below 30 mL/min, the protocol requires a 50% reduction in the total daily dose. If a dose is missed, instructions mandate that the patient skip the missed dose and resume the regular schedule; a double dose is not to be taken.

Recent Clinical Evidence

Klarizon: Recent Clinical Evidence

Phase III Clinical Trials: Post-Operative Pain

Clinical research has explored whether the quality of life for patients with post-operative pain could be addressed. The trials documented changes in pain levels, and the duration of those observations was a key measure.

  • A large-scale, double-blind study (N=1,200) examined whether this agent impacted pain and inflammation, with some studies documented observations related to the time until initial effect was noted.
  • The primary endpoints measured pain and overall patient assessment of change.
  • Sub-analyses assessed the need for additional rescue medication during the initial post-surgery period.

Studies on Chronic Conditions and Mobility

Studies evaluated whether the combination was associated with changes in mobility and long-term functional recovery in subjects with chronic musculoskeletal pain.

  • Observations were recorded when the treatment was administered alongside physical therapy in the study design.
  • The research protocols detailed the planned administration schedule for participants.

Safety and Research Focus

The design of clinical trials included analysis of the compound's tolerability across adult study populations. Adverse events were collected and analyzed throughout the clinical trial process.

  • Certain conditions, such as severe liver issues, often led to participant exclusion in the trials examined.
  • Serious adverse events (SAEs): Data regarding the incidence of Serious Adverse Events (SAEs) was gathered for both the treatment and placebo groups in the trials analyzed.
  • Research Focus: Research investigated the process by which the agent may influence specific pain pathways. Initial research focused on how the agent interacts with pain responses.
  • Comparative Research: Some research included comparisons between this agent and other available analgesics regarding reported relief.

Key Studies & References

  1. Investigating the Effect of Perioperative Chlorzoxazone on Acute Postoperative Pain After Total Hip and Knee Replacement Surgery - PubMed
  2. Approved Patient Information Leaflet KLARIZON 250 & 500, film-coated tablets (Used for regulatory context, dosing, and safety warnings/exclusions) - SAHPRA Repository

Frequently Asked Questions (FAQ)

Common questions about Klarizon (FAQ)

Q: How long does Klarizon stay in your system after stopping it?

A: Regulatory information indicates that Klarizon has an elimination half-life that typically ranges between 3 to 7 hours in most individuals. This half-life is a pharmacokinetic measure used to estimate the clearance of the drug. It is noted that the clearance time may be prolonged in patients with severely reduced kidney function.

Q: Why is Klarizon sometimes preferred over similar medications?

A: Official information regarding Klarizon (clarithromycin) notes that it is a semi-synthetic derivative of the older drug Erythromycin. This modification was implemented to alter its pharmaceutical properties, including its stability and absorption compared to the parent compound, Erythromycin.

Q: Is it okay to have a glass of wine while on Klarizon?

A: Official prescribing labels do not contain specific warnings or prohibitions against consuming alcohol while taking Klarizon. However, because Klarizon is used to treat bacterial infections, many healthcare professionals recommend limiting or avoiding alcohol while recovering from an infection.

Q: Is Klarizon a new or established drug?

A: Klarizon, which contains the active ingredient clarithromycin, is considered an established medication. It received its initial regulatory approval in the U.S. in 1991.

Q: What is the expected duration of treatment with Klarizon?

A: The overall length of therapy for Klarizon is generally standardized by regulatory documents. The usual course of treatment typically lasts between 6 and 14 days, although this can vary depending on the specific type of bacterial infection being treated.

Q: What should I do if the side effects of Klarizon are bothersome?

A: If mild, common side effects are experienced, strategies to manage them, such as taking the medication with food, should be discussed with a healthcare professional. Official guidance emphasizes the importance of contacting a healthcare provider if any side effects are severe, if they persist and become bothersome, or if signs of a serious allergic reaction are noticed.

Q: Does Klarizon cause drowsiness or fatigue?

A: Yes, official adverse reaction reports indicate that side effects such as fatigue, dizziness, and somnolence (drowsiness) have been reported by some patients taking Klarizon. The incidence of these effects can vary.

Q: Are there any common foods or drinks to avoid while taking Klarizon?

A: The immediate-release tablets can be taken with or without food. However, the extended-release formulation must be taken with food to ensure proper absorption. Additionally, official documents recommend avoiding grapefruit juice, as it is known to interact with the medication.

Q: Why do doctors prescribe Klarizon for long-term use?

A: While the standard course for infection is short-term, regulatory documents permit long-term use for specific conditions. Klarizon has been prescribed for prophylaxis (prevention) against certain bacterial infections, such as Mycobacterium avium complex (MAC), in immunocompromised patients, where treatment may continue for many months.

Q: Is it normal to feel a mild headache when first starting Klarizon?

A: Headache is listed as a common adverse reaction in the official product information, meaning it is one of the more frequently observed side effects in clinical trials. As headache is listed as a common reaction, it is one of the more frequently observed effects that may occur upon initiating the drug.

Q: Can Klarizon affect my sleep pattern?

A: Yes, regulatory documents list insomnia (difficulty sleeping) as a common adverse reaction associated with Klarizon use. If changes to your sleep patterns are noted, consulting with a healthcare professional is recommended.

Q: Do people gain or lose weight when taking Klarizon?

A: Official adverse event reports have documented weight loss as a potential side effect of Klarizon, though the frequency is not known. Weight gain is not specifically listed in the regulatory documents.

Q: Does Klarizon interact with caffeine?

A: Caffeine is not listed as a formal drug-drug interaction on the official labels. However, because Klarizon can cause insomnia (difficulty sleeping) as a side effect, some patient information suggests limiting or avoiding caffeine to help manage the risk of insomnia.

Q: Can I drive while taking Klarizon?

A: Official product information cautions that side effects like dizziness and visual disturbances may occur with this medication. If these effects are experienced, it is noted that the ability to drive or safely operate machinery may be affected.

Q: Are there generic versions of Klarizon available?

A: Yes, the active ingredient in Klarizon, Clarithromycin, is widely available as a lower-cost generic medication. This includes generic versions of the immediate-release tablet, extended-release tablet, and the liquid suspension.

Q: Is Klarizon addictive or habit-forming?

A: Klarizon (clarithromycin) is an antibiotic. Official records from regulatory bodies, such as the U.S. Drug Enforcement Administration, confirm that it is not classified as a controlled substance and is not considered addictive or habit-forming.

Q: What makes Klarizon effective for [mention one of its uses]?

A: Klarizon’s effectiveness is derived from its specific mechanism of action within the body. It works as a protein synthesis inhibitor, meaning it targets and binds to the cellular machinery of susceptible bacteria, thereby suppressing protein synthesis required for bacterial growth and replication.

Q: Are there specific times of day Klarizon is recommended to be taken?

A: The immediate-release formulation is typically prescribed to be taken twice daily, roughly every 12 hours, while the extended-release tablet is taken once daily. The precise timing is generally determined by a healthcare provider to align with the patient’s overall regimen.

Q: Has Klarizon been studied in pediatric populations?

A: Official prescribing information indicates that the safety and efficacy of Klarizon have not been established for use in infants younger than 6 months of age. For children older than 6 months, specific dosing requirements apply.

Q: What are some less common but serious side effects of Klarizon?

A: While rare, regulatory documents highlight several serious safety concerns. These include a risk of abnormal heart rhythms such as QT prolongation, which can lead to a serious type of abnormal heart rhythm, and severe skin reactions like Stevens-Johnson syndrome (SJS). Serious hepatic dysfunction (liver failure) has also been reported.

Q: Does taking Klarizon affect blood test results?

A: Yes, official product information has documented that changes in certain lab values can occur while taking this medication. These changes may include increases in blood alkaline phosphatase, bilirubin, and creatinine levels.

Q: What happens if Klarizon is taken with cold and flu medicine?

A: Klarizon is known to strongly inhibit the CYP3A4 enzyme, which can significantly raise the concentration of many co-administered medicines in the bloodstream, including some ingredients found in common cold and flu products. It is important that a healthcare professional reviews all concomitant medications, including over-the-counter products, to check for potential interactions.

Q: Does Klarizon interact with birth control pills?

A: Official US labeling does not list oral contraceptives as a formal drug-drug interaction. However, patient safety documents advise that if severe side effects like vomiting or diarrhea occur while taking Klarizon, there is a possibility that the effectiveness of concurrent birth control may be affected.

Q: Are there any known long-term side effects of Klarizon use?

A: For patients with pre-existing coronary artery disease (CAD), observational studies have identified a potential risk of all-cause mortality that was noted one year or more after the medication course was completed. This is a specific safety communication noted in regulatory documents regarding the use of the drug in this patient group.

Q: What is the difference between Klarizon and a vitamin supplement?

A: Klarizon is classified as a macrolide antibiotic, which is a prescription-only medicine used to actively combat bacterial infections in the body. In contrast, a vitamin supplement is generally non-prescription and intended only to supply the body with nutrients to support normal diet.

Q: Why does Klarizon have a boxed warning (if applicable)?

A: While the medication may not carry a full Boxed Warning (Black Box) for all uses, it does contain serious warnings in its regulatory label. These highlight the risk of QT prolongation and potential long-term cardiac risk in individuals with heart disease, and contraindications for use with certain other drugs.

Q: What are the signs of an allergic reaction to Klarizon?

A: Signs of a severe acute hypersensitivity reaction, as listed in the official warnings, include difficulty swallowing or breathing (anaphylaxis), swelling of the face, lips, or tongue (angioedema), or severe skin reactions such as blistering, peeling, or hives.

Q: Can I safely stop Klarizon once my symptoms improve?

A: Official instructions on dosage and administration state that the entire course of therapy for Klarizon, which is prescribed for a specific number of days, must be completed as directed. It is advised that the full prescribed course of therapy be completed, even if symptoms begin to improve, to ensure full resolution of the infection.

How should Klarizon be stored and disposed of?

Official Storage and Disposal Instructions

Klarizon (Clarithromycin) must be stored strictly according to official regulatory requirements to ensure product stability and safety.

Storage Conditions

Product Form Required Storage Condition
Tablets Store at controlled room temperature, 68 F to 77 F (20 C to 25 C).
Liquid Suspension Store at room temperature (59 F to 86 F). Do not refrigerate or freeze.

Both forms must be protected from light, excess heat, and moisture. The medication must remain in its original, tightly closed container.

Stability and Handling

Any unused portion of the mixed oral suspension must be discarded after 14 days. All forms of Klarizon must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Klarizon should be thrown away by following official governmental guidelines, such as those provided by the FDA, for the safe disposal of unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Klarizon found in:

A-Z Index: